Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Krebs Biochemicals & Industries Ltd Fundamentals

Market Cap
₹ 147.04 Cr
P/E Ratio (TTM)
0.00
P/B Ratio
0.00
Debt to Equity
0.78
ROE
0.00
EPS (TTM)
0.00
Dividend Yield
0.00 %
Book Value
-50.26

Click here to know more about Fundamentals

Krebs Biochemicals & Industries Ltd Financials

Krebs Biochemicals & Industries Ltd Financials

Krebs Biochemicals & Industries Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 72.75 % 72.75 % 72.75 % 72.75 %
Retail 20.11 % 19.00 % 18.80 % 18.54 %
Others 6.65 % 7.76 % 7.96 % 8.22 %
FII 0.49 % 0.49 % 0.49 % 0.49 %
Mutual Funds 0.00 % 0.00 % 0.00 % 0.00 %

Promoters

72.75%

Retail

20.11%

Others

6.65%

FII

0.49%

Mutual Funds

0.00%

Promoters

72.75%

Retail

19.00%

Others

7.76%

FII

0.49%

Mutual Funds

0.00%

Promoters

72.75%

Retail

18.80%

Others

7.96%

FII

0.49%

Mutual Funds

0.00%

Promoters

72.75%

Retail

18.54%

Others

8.22%

FII

0.49%

Mutual Funds

0.00%

Resistance and Support

₹67.90

PIVOT

resistance-arrow
Resistance
First Resistance₹68.800
Second Resistance₹69.400
Third Resistance₹70.300
support-arrow
Support
First Support₹67.300
Second Support₹66.400
Third Support₹65.800

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day4,0343,22756.50
Week1,3824,4932.64
1 Month1,3824,9682.64
6 Months1,874,3131,200,54268.51

About Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries Ltd (Formerly Krebs Biochemicals Ltd), promoted by R T Ravi in 1991 is engaged in the manufacture of Active Pharmaceutical Ingredients(API) through Fermentation process, one among very few in the world to do the same. Krebs develops commercially viable biotech processes for application in medicine, agriculture and industry. Undertaking contract manufacturing for large pharmaceutical and multinational companies and developing products for sale in global markets, the Company possesses expertise and infrastructure in chemical synthesis, fermentation and enzymatic technologies. KBIL which commenced commercial operations in the year 1994 with an installed capacity of 60 TPA has now grown to 150 TPA. KBL went to public with an IPO in 1994. During 2001-02, the company launched Vitamin C(I P Grade) through Fermentation Process. The Company commissioned 2.5 MW Co-generation Power Plant at Unit II in Vizag during 2003-04 and started operations on it from July, 2004 onwards.

Managing Director

1991

Founded

Jitendra Shah

NSE Symbol

KREBSBIO

Krebs Biochemicals & Industries Ltd Management

NameDesignation
G V L PrasadIndependent Director
R T RaviChairman (Non-Executive)
Avinash RaviNon Executive Director
Tangirala MalatiIndependent Director
Satish KhivsaraIndependent Director
Raj Kamal Prasad VermaIndependent Director
Rohit TapariaCompany Sec. & Compli. Officer
Jitendra ShahManaging Director
Keyur DoshiCompany Sec. & Compli. Officer

Krebs Biochemicals & Industries Ltd News

Krebs Biochemicals & Industries announces board meeting date
On 21 May 2024
Krebs Biochemicals & Industries reports standalone net loss of Rs 4.98 crore in the December 2023 quarter
Sales rise 42.79% to Rs 12.98 crore
Krebs Biochemicals & Industries to hold board meeting
On 12 February 2024
Krebs Biochemicals & Industries reports standalone net loss of Rs 3.57 crore in the September 2023 quarter
Sales decline 28.89% to Rs 14.89 crore
Krebs Biochemicals & Industries to convene board meeting
On 8 November 2023
Krebs Biochemicals & Industries to conduct AGM
On 27 September 2023
Krebs Biochemicals & Industries reports standalone net loss of Rs 5.33 crore in the June 2023 quarter
Sales decline 0.56% to Rs 10.58 crore
Krebs Biochemicals & Industries to conduct board meeting
On 9 August 2023
Krebs Biochemicals & Industries reports standalone net loss of Rs 6.94 crore in the March 2023 quarter
Sales decline 40.19% to Rs 11.46 crore
Krebs Biochemicals & Industries to convene board meeting
On 24 May 2023

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
Sun Pharmaceuticals Industries Ltd₹ 367554.12 Cr
₹ 1,531.90
(0.03 %)
89.16
Cipla Ltd₹ 113362.29 Cr
₹ 1,404.05
(0.36 %)
30.52
Zydus Lifesciences Ltd₹ 111083.2 Cr
₹ 1,103.95
(5.00 %)
41.35
Divis Laboratories Ltd₹ 104302.61 Cr
₹ 3,929.00
(0.47 %)
76.42
Dr Reddys Laboratories Ltd₹ 96948.1 Cr
₹ 5,811.60
(0.21 %)
22.34

Krebs Biochemicals & Industries Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Krebs Biochemicals & Industries Ltd shares in BlinkX

Krebs Biochemicals & Industries Ltd's P/E ratio is 0.00 times as of May 18, 2024 at 01:44 PM.

Krebs Biochemicals & Industries Ltd's most recent financial reports indicate a price-to-book ratio of 0.00, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Krebs Biochemicals & Industries Ltd's market is 147 Cr as on May 18, 2024 at 01:44 PM.

The current financial records of Krebs Biochemicals & Industries Ltd show a 0.00% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

According to Krebs Biochemicals & Industries Ltd's most recent financial filings, the company has a total asset value of Crores, which includes current and non-current assets such as inventory, cash, properties, and equipment.

As of the Mar 2024 quarter, the promoter shareholding in Krebs Biochemicals & Industries Ltd stands at 72.75%. During the same period, Institutional Investors have shown a slight values are equal in their holdings, values are equal from 0.49% to 0.49%.